Crinetics Pharmaceuticals reported that its first‑line oral therapy, PALSONIFY, generated more than $5 million in unaudited net product revenue during the fourth quarter of 2025, the first commercial quarter after the drug’s FDA approval in the third quarter of 2025. The revenue figure reflects a robust uptake in the early months of the launch, with more than 200 enrollment forms submitted and a broad prescriber base adopting the product, indicating strong market penetration.
The company’s enrollment data underscore the commercial momentum: over 200 prescriber enrollment forms were received within the first three months of the launch, and early sales data show that prescribers are incorporating PALSONIFY into routine treatment plans. This level of prescriber engagement is a key driver of the $5 million revenue milestone, as it translates into immediate patient access and sales volume.
In addition to the commercial success, Crinetics disclosed topline results from the fourth cohort of its Phase 2 trial of atumelnant for classic congenital adrenal hyperplasia. An 80 mg once‑daily dose produced a 67 % mean reduction in androstenedione levels and enabled 88 % of participants to lower their glucocorticoid doses to physiologic replacement levels over 12 weeks. No hepatic transaminase adverse events were reported, highlighting a favorable safety profile for the drug.
The clinical data suggest that atumelnant could offer a differentiated treatment option that improves disease control while reducing steroid exposure. The high rate of glucocorticoid dose reduction and the absence of liver toxicity are significant because current standard therapies rely heavily on chronic steroid use, which carries long‑term health risks. These results position atumelnant as a strong candidate to capture a sizable share of the congenital adrenal hyperplasia market.
Crinetics’ dual milestones—first commercial revenue for PALSONIFY and encouraging Phase 2 data for atumelnant—signal momentum for both its commercial and pipeline programs. The early revenue demonstrates the company’s ability to translate regulatory approval into sales, while the atumelnant results reinforce its pipeline strength and provide a potential growth engine for the future.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.